<DOC>
	<DOCNO>NCT00004705</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine stability uridine triphosphate ( UTP ) examine metabolism exogenous nucleotide airway epithelial surface patient cystic fibrosis . II . Determine acute safety efficacy aerosolize UTP child cystic fibrosis .</brief_summary>
	<brief_title>Study Uridine Triphosphate ( UTP ) Aerosol Spray Cystic Fibrosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients may treat three different regimen . Patients may treat one regimen , meet eligibility requirement . Patients regimen A adult receive uridine triphosphate ( UTP ) inhalation , follow immediately bronchoscopy . Patients regimen B child , age 4 10 year . Patients receive 4 graded dos UTP inhalation day 1 . On day 2 , patient receive single dose UTP . Patients receive amiloride follow UTP inhalation day 3 . Patients regimen C child , age 4 18 year . Patients inhale radiolabelled ( technetium 99m ) monodisperse iron oxide aerosol . Radiation deposit patient 's lung monitor . Patients randomize receive one 4 different aerosol ( vehicle ; UTP ; amiloride ; UTP plus amiloride ) , inhale 20 minute . Patients follow 24 hour aerosol exposure . Regimen D dose escalation study patient age 9 40 year . Patients receive either vehicle UTP inhalation 3 time daily 3 day . Cohorts 4 patient enter dose level .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Amiloride</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis mild moderate cystic fibrosis Small production daily airway secretion Stable pulmonary course Prior/Concurrent Therapy Radiotherapy : No radiation within 12 month cause patient exceed annual limit Other : No chronic medication reactive airway disease At least 12 hour since inhale betaadrenergic agonist At least 24 hour since systemic theophylline Patient Characteristics FEV1 great 50 % predict Other : Not pregnant Must perform reproducible spirometry</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1999</verification_date>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>rare disease</keyword>
</DOC>